SKYE BIOSCIENCE INC
SKYENASDAQ🏆 #4939 by market capEarnings Nov 9US Equity
$1.51▲ $0.00 (+0.33%)
Market closed · at closeTrack SKYE
Get earnings, price moves & breaking news on Telegram
24h▲ 0.3%
7d▼ 6.5%
14d▼ 4.4%
30d▼ 4.7%
ytd▼ 74.7%
1y▼ 88.2%
🏦Market Cap
$7M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
39.3%
Healthy
💵FCF Margin
—
⚖️P/S Ratio
24.0x
Expensive
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $1.50 – $1.51
- 52-Week Range
- $1.45 – $13.28
- Volume (shares)
- 375
- Avg Volume (shares)
- —
- Shares Outstanding
- 4.4M
- Next Earnings
- 2026-11-09
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 24.0x
- EPS (TTM)
- $-7.93
- Dividend Yield
- —
- Dilution (1yr)
- −0.8%
SKYE BIOSCIENCE INC
SKYEFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$58M▲ +92.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$43M▲ +60.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
5.0M▼ −0.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$6M▼ −$62M YoY
StockOtter · stockotter.spaceAbout SKYE BIOSCIENCE INC
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💎Quality★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
10 analysts
Strong Buy2
Buy5
Hold3
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.